WO2014165190A3 - Compositions comprising docosapentaenoic acid and methods of use - Google Patents

Compositions comprising docosapentaenoic acid and methods of use Download PDF

Info

Publication number
WO2014165190A3
WO2014165190A3 PCT/US2014/024712 US2014024712W WO2014165190A3 WO 2014165190 A3 WO2014165190 A3 WO 2014165190A3 US 2014024712 W US2014024712 W US 2014024712W WO 2014165190 A3 WO2014165190 A3 WO 2014165190A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
docosapentaenoic acid
acid
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/024712
Other languages
French (fr)
Other versions
WO2014165190A2 (en
Inventor
Abdel Aziz FAWZY
George Bobotas
Ihor Terleckyj
Roelof Rongen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Priority to CA2905795A priority Critical patent/CA2905795A1/en
Priority to JP2016501615A priority patent/JP2016512544A/en
Priority to EP14779339.2A priority patent/EP2986148A2/en
Publication of WO2014165190A2 publication Critical patent/WO2014165190A2/en
Publication of WO2014165190A3 publication Critical patent/WO2014165190A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Edible Oils And Fats (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Orally administrable composition comprising fatty acids comprising docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA). The compositions can be used for the treatment or prophylaxis of a variety of conditions, including liver-related conditions.
PCT/US2014/024712 2013-03-13 2014-03-12 Compositions comprising docosapentaenoic acid and methods of use Ceased WO2014165190A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2905795A CA2905795A1 (en) 2013-03-13 2014-03-12 Compositions comprising docosapentaenoic acid and methods of use
JP2016501615A JP2016512544A (en) 2013-03-13 2014-03-12 Compositions containing docosapentaenoic acid and methods of use
EP14779339.2A EP2986148A2 (en) 2013-03-13 2014-03-12 Compositions comprising docosapentaenoic acid and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780948P 2013-03-13 2013-03-13
US61/780,948 2013-03-13

Publications (2)

Publication Number Publication Date
WO2014165190A2 WO2014165190A2 (en) 2014-10-09
WO2014165190A3 true WO2014165190A3 (en) 2015-01-29

Family

ID=51537458

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2013/075704 Ceased WO2014158256A1 (en) 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use
PCT/US2013/075661 Ceased WO2014143272A1 (en) 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use
PCT/US2013/075740 Ceased WO2014143275A1 (en) 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use
PCT/US2014/024712 Ceased WO2014165190A2 (en) 2013-03-13 2014-03-12 Compositions comprising docosapentaenoic acid and methods of use

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/US2013/075704 Ceased WO2014158256A1 (en) 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use
PCT/US2013/075661 Ceased WO2014143272A1 (en) 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use
PCT/US2013/075740 Ceased WO2014143275A1 (en) 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use

Country Status (4)

Country Link
EP (2) EP2968246A4 (en)
JP (2) JP2016518315A (en)
CA (2) CA2905671A1 (en)
WO (4) WO2014158256A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3233074T3 (en) 2014-12-15 2023-02-06 Dsm Ip Assets B.V. Treatment for non-alcoholic fatty liver diseases
CN106692973A (en) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 A kind of composition and its use, pharmaceutical preparation
EP3456328A4 (en) * 2016-05-10 2020-02-26 Shenzhen Hightide Biopharmaceutical., Ltd. COMPOSITION, AND PHARMACEUTICAL APPLICATION AND PREPARATION THEREOF
KR20190113520A (en) * 2017-02-09 2019-10-08 에스.엘.에이. 파르마 에이지 Reduction of Fecal Calprotectin Level and Prevention of Clinical Recurrence in Patients with Ulcerative Colitis of Highly Refined Eicosapentaenoic Acid as Free Fatty Acid
CN107006809B (en) * 2017-04-11 2020-06-09 江南大学 Vinegar onion product with blood fat reducing effect and preparation method thereof
JP7099821B2 (en) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 PCSK9 inhibitor and food composition for improving cholesterol metabolism
PE20250163A1 (en) * 2019-10-25 2025-01-22 Nuseed Nutritional Us Inc ENRICHED COMPOSITIONS OF POLYUNSATURATED FATTY ACIDS
CN118993893B (en) * 2024-08-07 2025-06-17 蓝平 EPA derivative and its preparation method and use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054329A1 (en) * 2005-11-17 2009-02-26 N.V. Nutricia Composition with docosapentaenoic acid
US20100062107A1 (en) * 2006-09-14 2010-03-11 Dong-Hun Yoon Glyceride oil composition from fish oil and preparation method thereof
US20130005757A1 (en) * 2009-04-29 2013-01-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104856A1 (en) * 2003-05-05 2007-05-10 Hakon Standal Fish oils with an altered fatty acid profile, method of producing same and their use
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
BRPI0516803A (en) * 2004-11-19 2008-09-23 Martek Biosciences Corp long chain polyunsaturated fatty acid oxylipines and their methods of production and use
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
KR101383006B1 (en) * 2009-02-10 2014-04-08 아마린 파마, 인크. Methods of treating hypertriglyceridemia
ES2894340T3 (en) * 2009-03-09 2022-02-14 Basf As Compositions comprising a mixture of fatty acid oils and a surfactant, and methods and uses thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
WO2011050474A1 (en) * 2009-10-29 2011-05-05 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
US8846604B2 (en) * 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content
EP2861227A4 (en) * 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054329A1 (en) * 2005-11-17 2009-02-26 N.V. Nutricia Composition with docosapentaenoic acid
US20100062107A1 (en) * 2006-09-14 2010-03-11 Dong-Hun Yoon Glyceride oil composition from fish oil and preparation method thereof
US20130005757A1 (en) * 2009-04-29 2013-01-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Also Published As

Publication number Publication date
WO2014143275A1 (en) 2014-09-18
JP2016518315A (en) 2016-06-23
WO2014165190A2 (en) 2014-10-09
CA2905671A1 (en) 2014-09-18
JP2016512544A (en) 2016-04-28
CA2905795A1 (en) 2014-10-09
EP2986148A2 (en) 2016-02-24
WO2014158256A1 (en) 2014-10-02
EP2968246A4 (en) 2016-08-03
EP2968246A1 (en) 2016-01-20
WO2014143272A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
WO2014165190A3 (en) Compositions comprising docosapentaenoic acid and methods of use
PH12016501194B1 (en) Lipid comprising long chain polyunsaturated fatty acids
HK1198515A1 (en) Fatty acid compositions
UA114615C2 (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
ZA201704820B (en) Process for increasing the stability of a composition comprising polyunsaturated omega-3 fatty acids
EP3022310A4 (en) Microorganisms and methods for the production of fatty acids and fatty acid derived products
EP3149105A4 (en) Using synthetic acid compositions as alternatives to conventional acids tn the oil and gas industry
WO2014057362A3 (en) Omega -3 compositions
ZA201704821B (en) Process for increasing the stability of a composition comprising polyunsaturated omega-6 fatty acids
EP3661600A4 (en) Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
ZA201702385B (en) Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
MX2015011767A (en) Compositions of crude algal oil.
PL3219316T3 (en) Mixture of fatty acids (f.a.g., fatty acids group) for use in the treatment of inflammatory pathologies
WO2016089206A3 (en) Selective il-6-trans-signalling inhibitor compositions
MX2021001790A (en) Solid compositions of triglycerides and uses thereof.
WO2014108337A8 (en) Pyrazolyl-based carboxamides i as crac channel inhibitors
PL3809860T3 (en) Dha enriched polyunsaturated fatty acid compositions
IL263982B (en) Two components compositions comprising acetylsalicylic acid and salts organic acids
HK1244218A1 (en) Millicapsule formulations comprising polyunsaturated free fatty acids
EP3201288A4 (en) Synthetic acid compositions alternatives to conventional acids in the oil and gas industry
EP3201287A4 (en) Synthetic acid compositions alternatives to conventional acids in the oil and gas industry
PL3560342T3 (en) Dha enriched polyunsaturated fatty acid compositions
AR100028A1 (en) NUTRITIONAL COMPOSITIONS CONTAINING ESTEARIDÓNIC ACID
EP3027180A4 (en) Compositions and methods of the treatment of fatty acid metabolism disorders
WO2014108336A8 (en) Pyrazolyl-based carboxamides ii as crac channel inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14779339

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2905795

Country of ref document: CA

Ref document number: 2016501615

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014779339

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014779339

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14779339

Country of ref document: EP

Kind code of ref document: A2